| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
SAPE uses ultrasonic oscillation of microspheres in conjunction with tumor companion diagnostic factor capture antibodies for a duration of 20 seconds in order to detect tumors [1]. (2) Maintain microspheres in assay buffer at a 50 microspheres/µL final concentration. Pour 50 µL of the detection buffer and 50 µL of the standard as a control into each well of the 96-well plate. (3) Incubate at 800 rpm/min for 30 minutes at room temperature. (4) After 30 to 60 seconds on the magnetic separation plate, filter out the supernatant and repeat the washing process twice, using 100 μL of reaction buffer each time. Fifth, thoroughly mix in 50 µL of detection buffer. (6) Add 50 µL to each well after diluting the biotinylated detection antibody with detection buffer to 4 µg/mL. (7) Incubate at 800 rpm/min for 30 minutes at room temperature. (8) After 30 to 60 seconds on the magnetic separation plate, remove the supernatant and wash twice, using 100 μL of reaction buffer each time. Add 50 µL of detection buffer and thoroughly mix. (10) Add 50 µL to each well after diluting SAPE with detection buffer to 4 µg/mL. (11) Incubate at 800 rpm/min for 30 minutes at room temperature. Once the magnetic separation plate has been placed on it for 30 to 60 seconds, remove the supernatant and wash twice, using 100 μL of reaction buffer each time. (13) Include 100 µL of detection buffer and thoroughly stir. (14) Luminex magnetic microspheres' fluorescence encoding signal and SAPE's reporter fluorescence signal should be excited. A high-sensitivity CCD imaging device or flow analysis device and software should then be used to perform Luminex magnetic microsphere classification and result detection using a particular algorithm.
|
|---|---|
| References | |
| Additional Infomation |
1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine zwitterion is a phosphatidylethanolamine 38:4 zwitterion obtained by transfer of a proton from the phosphate to the primary amino group of 1-octadecanoyl-2-(5Z,8Z,11Z,14Z-icosatetraenoyl)-sn-glycero-3-phosphoethanolamine; major species at pH 7.3. It is a phosphatidylethanolamine 38:4 zwitterion and a 1-stearoyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion. It is a tautomer of a 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine.
|
| Molecular Formula |
C43H78NO8P
|
|---|---|
| Molecular Weight |
768.06
|
| Exact Mass |
767.546
|
| CAS # |
61216-62-4
|
| PubChem CID |
46891781
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
776.1±70.0 °C at 760 mmHg
|
| Flash Point |
423.2±35.7 °C
|
| Vapour Pressure |
0.0±5.8 mmHg at 25°C
|
| Index of Refraction |
1.493
|
| LogP |
14.62
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
53
|
| Complexity |
1000
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[NH3+])OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC
|
| InChi Key |
ANRKEHNWXKCXDB-BHFWLYLHSA-N
|
| InChi Code |
InChI=1S/C43H78NO8P/c1-3-5-7-9-11-13-15-17-19-20-22-24-26-28-30-32-34-36-43(46)52-41(40-51-53(47,48)50-38-37-44)39-49-42(45)35-33-31-29-27-25-23-21-18-16-14-12-10-8-6-4-2/h11,13,17,19,22,24,28,30,41H,3-10,12,14-16,18,20-21,23,25-27,29,31-40,44H2,1-2H3,(H,47,48)/b13-11-,19-17-,24-22-,30-28-/t41-/m1/s1
|
| Chemical Name |
2-azaniumylethyl [(2R)-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxy-3-octadecanoyloxypropyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3020 mL | 6.5099 mL | 13.0198 mL | |
| 5 mM | 0.2604 mL | 1.3020 mL | 2.6040 mL | |
| 10 mM | 0.1302 mL | 0.6510 mL | 1.3020 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
